Sugi Predict

Sugi Predict / Targets / KLK1

KLK1

Kallikrein-1 · P06870 · KLK1 on Sugi Atlas →

38,741 patent compounds predicted against KLK1, 23,575 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL614075 SCHEMBL614075 0.56 12/20
SCHEMBL614076 SCHEMBL614076 0.56 12/20
SCHEMBL618863 SCHEMBL618863 0.49 9/20
SCHEMBL111906 SCHEMBL111906 0.53 7/20
Camostat Camostat (SCHEMBL871583) 0.72 5/20
Camostat Camostat (SCHEMBL125270) 1.00 4/20
Camostat Camostat (SCHEMBL125269) 0.68 4/20
SCHEMBL904391 SCHEMBL904391 0.47 4/20
SCHEMBL327252 SCHEMBL327252 0.44 4/20
SCHEMBL112651 SCHEMBL112651 0.34 4/20
SCHEMBL392725 SCHEMBL392725 0.70 3/20
SCHEMBL393834 SCHEMBL393834 0.68 3/20
SCHEMBL394113 SCHEMBL394113 0.68 3/20
SCHEMBL392647 SCHEMBL392647 0.67 3/20
SCHEMBL392648 SCHEMBL392648 0.67 3/20
SCHEMBL392809 SCHEMBL392809 0.66 3/20
Nafamostat Nafamostat (SCHEMBL135503) 0.64 3/20
Nafamostat Nafamostat (SCHEMBL564665) 0.64 3/20
SCHEMBL393387 SCHEMBL393387 0.64 3/20
SCHEMBL408644 SCHEMBL408644 0.63 3/20

Clinical trials — most relevant to KLK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment PHASE3NOT_YET_RECRUITING
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II PHASE3COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer PHASE2WITHDRAWN
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke PHASE2COMPLETED
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer PHASE2COMPLETED
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC PHASE1/PHASE2RECRUITING
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance PHASE2COMPLETED
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma PHASE2COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer PHASE1COMPLETED
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents PHASE1SUSPENDED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population nanRECRUITING
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen) nanENROLLING_BY_INVITATION
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland nanUNKNOWN
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
KIDney Injury in Times of COVID-19 (KIDCOV) nanRECRUITING
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KLK1 binder may also engage these)

ProteinNameSimilarity
Q28773 — 1.000 Q28773 →
Q07276 — 0.999 Q07276 →
KLK3 Prostate-specific antigen 0.994 landscape →
KLK2 Kallikrein-2 0.992 landscape →
P36369 — 0.990 P36369 →
P09582 — 0.990 P09582 →
Q76B45 — 0.990 Q76B45 →
P36373 — 0.989 P36373 →
P00758 — 0.989 P00758 →
P36376 — 0.988 P36376 →
P36374 — 0.988 P36374 →
P36368 — 0.987 P36368 →
P33619 — 0.987 P33619 →
P00752 — 0.985 P00752 →
Q5FBW2 — 0.985 Q5FBW2 →
Q6DT45 — 0.985 Q6DT45 →
P27435 — 0.985 P27435 →
P36375 — 0.985 P36375 →
Q5FBW1 — 0.984 Q5FBW1 →
P97592 — 0.984 P97592 →
P00756 — 0.984 P00756 →
Q02844 — 0.983 Q02844 →
P04071 — 0.982 P04071 →
P50342 — 0.982 P50342 →
P09650 — 0.982 P09650 →
P15947 — 0.982 P15947 →
P43430 — 0.982 P43430 →
P00755 — 0.982 P00755 →
P00770 — 0.982 P00770 →
KLK6 Kallikrein-6 0.982 landscape →